| |
 |
Editorial:[Hot Topic: The Role of Radiopharmaceuticals in Drug Discovery and Development(Executive Editor: Kalevi Kairemo)]
|
| |
|
pp.926-927 (2) Author: Kalevi Kairemo
|
| |
|
|
| |
|
Microdosing, Imaging Biomarkers and SPECT: A Multi-Sided Tripod to Accelerate Drug Development
|
| |
|
pp.928-934 (7) Authors: Ernest K.J. Pauwels, Kim Bergstrom, Giuliano Mariani, Kalevi Kairemo
|
| |
|
|
| |
|
Cardiovascular Drug Development Using Radiopharmaceuticals
|
| |
|
pp.935-942 (8) Authors: Heikki Ukkonen, Keiichiro Yoshinaga, Jean N. DaSilva, Rob S.B. Beanlands, Juhani Knuuti
|
| |
|
|
| |
|
Role of Radiopharmaceuticals in Development of Inhaled Drugs
|
| |
|
pp.943-949 (7) Author: Antti P. Jekunen
|
| |
|
|
| |
|
Cancer Drug Development with the Help of Radiopharmaceuticals: Academic Experience
|
| |
|
pp.950-956 (7) Author: Steven M. Larson
|
| |
|
|
| |
|
Radiopharmaceuticals for Oncology Drug Development: A Pharmaceutical Industry Perspective
|
| |
|
pp.957-965 (9) Authors: Philip S. Murphy, Mats Bergstrom
|
| |
|
|
| |
|
Defining Pharmacokinetics for Individual Patient Dosimetry in Routine Radiopeptide and Radioimmunotherapy of Cancer: Australian Experience
|
| |
|
pp.966-982 (17) Author: J. Harvey Turner
|
| |
|
|
| |
|
Cancer Drug Development Using Glucose Metabolism Radiopharmaceuticals
|
| |
|
pp.983-987 (5) Authors: Y. Y. Sun, Y. Chen
|
| |
|
|
| |
|
Development of a PBPK Model for Monoclonal Antibodies and Simulation of Human and Mice PBPK of a Radiolabelled Monoclonal Antibody
|
| |
|
pp.988-1007 (20) Authors: Tomi Heiskanen, Tomas Heiskanen, Kalevi Kairemo
|
| |
|
|
| |
|
Vanilloid Receptor Antagonists: Emerging Class of Novel Anti-Inflammatory Agents for Pain Management
|
| |
|
pp.1008-1026 (19) Authors: Manojit Pal, Sowjanya Angaru, Arumugam Kodimuthali, Nidhi Dhingra
|
| |
|
|
| |
|
Atheroprotective Properties of Pigment Epithelium-Derived Factor (PEDF) in Cardiometabolic Disorders
|
| |
|
pp.1027-1033 (7) Authors: Sho-ichi Yamagishi, Takanori Matsui, Kazuo Nakamura
|
| |
|
|
